A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet

A Dose-response Evaluation of ALK Tree AIT

The primary aim of this trial is to evaluate the dose-response relationship for the ALK tree AIT administered once daily in order to define a dose-range that would be suitable for at-home administration.

Inclusion Criteria:

• A history of moderate to severe birch pollen allergy
• Use of symptomatic medication for treatment of birch pollen allergy
• Positive skin prick test to birch extract
• Positive specific IgE against Bet v 1

Exclusion Criteria:

• Overlapping perennial allergies
• History of uncontrolled asthma within the last 3 months
• FEV1 < 70% of predicted value in adults or FEV1 < 80% of predicted value in adolescents
• Previous or ongoing treatment with immunotherapy